卡瑞利珠单抗联合化疗对晚期肺鳞癌患者血清肿瘤标志物水平及预后的影响

Effects of Camrelizumab Combined with Chemotherapy on Serum Tumor Marker Levels and Prognosis in Patients with Advanced Lung Squamous Cell Carcinoma

目的探讨卡瑞利珠单抗联合化疗对晚期肺鳞癌患者血清肿瘤标志物水平及预后的影响。方法选择2020年1月至2021年1月本院收治的110例晚期肺鳞癌患者,进行随访分组。对照组(n=55)予以常规化疗方案,基于此,观察组(n=55)加用卡瑞利珠单抗。比较两组近期疗效、血清肿瘤标志物[血清癌胚抗原(CEA)、糖类抗原125(CA125)]、毒副反应及预后情况。结果观察组近期疾病控制率(98.18%)高于对照组(85.45%),不良反应发生率(3.64%)低于对照组(16.36%),差异有统计学意义(P<0.05)。两组治疗后肿瘤标志物水平均降低,且观察组CEA为(10.62±1.71)ng/ml、CA125为(37.92±4.15)U/ml低于对照组的(18.28±2.13)ng/ml、(68.76±6.23)U/ml,差异有统计学意义(P<0.05)。随访1年,观察组生存率为87.27%(48/55)高于对照组的65.45%(36/55),差异有统计学意义(P<0.05)。结论晚期肺鳞癌患者采用卡瑞利珠单抗联合化疗可增强治疗效果,改善血清肿瘤标志物水平,提升患者生存率,减少毒副反应,值得临床广泛应用。

Objective To investigate the effect of camrelizumab combined with chemotherapy on serum tumor marker levels and prognosis in patients with advanced lung squamous cell carcinoma.Methods A total of 110 patients with advanced squamous cell carcinoma of the lung admitted to our hospital from January 2020 to January 2021 were selected for follow-up grouping.The control group(n=55)was given conventional chemotherapy,based on this,the observation group(n=55)was given camrelizumab.The short-term efficacy,serum tumor markers[serum carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)],toxic and side effects and prognosis were compared between the two groups.Results The recent disease control rate(98.18%)in the observation group was higher than that in the control group(85.45%),and the incidence of adverse reactions(3.64%)was lower than that in the control group(16.36%),with a statistically significant difference(P<0.05).The levels of tumor markers in both groups decreased after treatment,and the CEA of the observation group was(10.62±1.71)ng/ml,and the CA125 was(37.92±4.15)U/ml lower than those of the control group(18.28±2.13)ng/mL,(68.76±6.23)U/ml,the difference was statistically significant(P<0.05).After 1-year follow-up,the survival rate of the observation group was 87.27%(48/55),which was higher than that of the control group,65.45%(36/55),and the difference was statistically significant(P<0.05).Conclusion Camrelizumab combined with chemotherapy in patients with advanced lung squamous cell carcinoma can enhance the therapeutic effect,improve the level of serum tumor markers,improve the survival rate of patients,and reduce the toxic and side effects,which is worthy of wide clinical application.